MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 10, 2004; DOI: 10.1124/mol.104.001586


0026-895X/04/6605-1123-1137$20.00
Mol Pharmacol 66:1123-1137, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.001586v1
66/5/1123    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carrillo, J. J.
Right arrow Articles by Milligan, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carrillo, J. J.
Right arrow Articles by Milligan, G.

Multiple Interactions between Transmembrane Helices Generate the Oligomeric {alpha}1b-Adrenoceptor

Juan J. Carrillo1, Juan F. López-Giménez, and Graeme Milligan

Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom

Combinations of coimmunoprecipitation, single-cell fluorescence resonance energy transfer, and cell-surface time-resolved fluorescence resonance energy transfer demonstrated protein-protein interactions and quaternary structure for the {alpha}1b-adrenoceptor. Self-association of transmembrane domain 1 and its interaction with the full-length receptor indicated a symmetrical interface provided by this domain. Lack of effect of mutation of the glycophorin-A dimerization-like region within this helix demonstrated that this did not provide the molecular mechanism. Multiple interactions were observed between the {alpha}1b-adrenoceptor and fragments derived from its sequence. Fragments comprising transmembrane domains 3 and 4 and transmembrane domains 5 and 6, but not transmembrane domain 7, were also able to interact with the full-length receptor. Transmembrane domain 7 failed to interact significantly with any element of the receptor and was not transported to the cell surface after coexpression with the full-length receptor. Symmetrical interactions were also noted between fragments incorporating transmembrane domain 4, but this segment of the receptor failed to interact with transmembrane domains 1 and 2 or transmembrane domains 5 and 6. Time-resolved fluorescence resonance energy transfer studies were also consistent with contributions of transmembrane domains 1 and/or 2 and transmembrane domains 3 and/or 4 to protein-protein interactions within the quaternary structure of the {alpha}1b-adrenoceptor, and with a contribution of transmembrane domains 5 and/or 6. These data are consistent with a complex oligomeric quaternary structure of the {alpha}1b-adrenoceptor in which major, symmetrical interactions may define intradimeric contacts with other contributions, providing interdimer contacts to generate oligomeric complexes akin to those observed for murine rhodopsin. A model derived from this was developed.


Received April 20, 2004; accepted August 3, 2004

Address correspondence to: Dr. Graeme Milligan, Molecular Pharmacology Group, Davidson Building, University of Glasgow, Glasgow G12 8QQ, Scotland, U.K. E-mail: g.milligan{at}bio.gla.ac.uk




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
J. F. Lopez-Gimenez, M. Canals, J. D. Pediani, and G. Milligan
The {alpha}1b-Adrenoceptor Exists as a Higher-Order Oligomer: Effective Oligomerization Is Required for Receptor Maturation, Surface Delivery, and Function
Mol. Pharmacol., April 1, 2007; 71(4): 1015 - 1029.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Ellis, J. D. Pediani, M. Canals, S. Milasta, and G. Milligan
Orexin-1 Receptor-Cannabinoid CB1 Receptor Heterodimerization Results in Both Ligand-dependent and -independent Coordinated Alterations of Receptor Localization and Function
J. Biol. Chem., December 15, 2006; 281(50): 38812 - 38824.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
K. R Sedgley, A. R Finch, C. J Caunt, and C. A McArdle
Intracellular gonadotropin-releasing hormone receptors in breast cancer and gonadotrope lineage cells
J. Endocrinol., December 1, 2006; 191(3): 625 - 636.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Canals, L. Jenkins, E. Kellett, and G. Milligan
Up-regulation of the Angiotensin II Type 1 Receptor by the MAS Proto-oncogene Is Due to Constitutive Activation of Gq/G11 by MAS
J. Biol. Chem., June 16, 2006; 281(24): 16757 - 16767.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
K. G. Harikumar, M. M. Morfis, C. S. Lisenbee, P. M. Sexton, and L. J. Miller
Constitutive Formation of Oligomeric Complexes between Family B G Protein-Coupled Vasoactive Intestinal Polypeptide and Secretin Receptors
Mol. Pharmacol., January 1, 2006; 69(1): 363 - 373.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Herrick-Davis, E. Grinde, T. J. Harrigan, and J. E. Mazurkiewicz
Inhibition of Serotonin 5-Hydroxytryptamine2C Receptor Function through Heterodimerization: RECEPTOR DIMERS BIND TWO MOLECULES OF LIGAND AND ONE G-PROTEIN
J. Biol. Chem., December 2, 2005; 280(48): 40144 - 40151.
[Abstract] [Full Text] [PDF]


Home page
Eukaryot CellHome page
M. C. Overton, S. L. Chinault, and K. J. Blumer
Oligomerization of G-Protein-Coupled Receptors: Lessons from the Yeast Saccharomyces cerevisiae
Eukaryot. Cell, December 1, 2005; 4(12): 1963 - 1970.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. F. O'Dowd, X. Ji, M. Alijaniaram, R. D. Rajaram, M. M. C. Kong, A. Rashid, T. Nguyen, and S. R. George
Dopamine Receptor Oligomerization Visualized in Living Cells
J. Biol. Chem., November 4, 2005; 280(44): 37225 - 37235.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. Pascal and G. Milligan
Functional Complementation and the Analysis of Opioid Receptor Homodimerization
Mol. Pharmacol., September 1, 2005; 68(3): 905 - 915.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Wilson, G. Wilkinson, and G. Milligan
The CXCR1 and CXCR2 Receptors Form Constitutive Homo- and Heterodimers Selectively and with Equal Apparent Affinities
J. Biol. Chem., August 5, 2005; 280(31): 28663 - 28674.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. M. Pietila, J. T. Tuusa, P. M. Apaja, J. T. Aatsinki, A. E. Hakalahti, H. J. Rajaniemi, and U. E. Petaja-Repo
Inefficient Maturation of the Rat Luteinizing Hormone Receptor: A PUTATIVE WAY TO REGULATE RECEPTOR NUMBERS AT THE CELL SURFACE
J. Biol. Chem., July 15, 2005; 280(28): 26622 - 26629.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Li, N. M. Nowak, S.-K. Kim, K. A. Jacobson, A. Bagheri, C. Schmidt, and J. Wess
Random Mutagenesis of the M3 Muscarinic Acetylcholine Receptor Expressed in Yeast: IDENTIFICATION OF SECOND-SITE MUTATIONS THAT RESTORE FUNCTION TO A COUPLING-DEFICIENT MUTANT M3 RECEPTOR
J. Biol. Chem., February 18, 2005; 280(7): 5664 - 5675.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Jastrzebska, T. Maeda, L. Zhu, D. Fotiadis, S. Filipek, A. Engel, R. E. Stenkamp, and K. Palczewski
Functional Characterization of Rhodopsin Monomers and Dimers in Detergents
J. Biol. Chem., December 24, 2004; 279(52): 54663 - 54675.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. A. Javitch
The Ants Go Marching Two by Two: Oligomeric Structure of G-Protein-Coupled Receptors
Mol. Pharmacol., November 1, 2004; 66(5): 1077 - 1082.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics